4－去甲氧基柔红霉素联合化疗治疗急性白血病的临床观察  

CLINICAL EVALUATION OF IDARUBICIN INCOMBINATION CHEMOTHERAPY FOR ACUTELEUKEMIA

作　　者：赵永强[1] 潘家绮[1] 许莹[1] 沈悌[1] 刘沛新[1] 苏荣[1] 张伯龙[1] 陈书长[1] 武永吉[1] 单渊东[1] 张之南[1] 

机构地区：[1]北京协和医院,北京平谷医院,内蒙古医学院第一附属医院

出　　处：《中华血液学杂志》1995年第7期344-346,共3页Chinese Journal of Hematology

摘　　要：１９９２年３月～１９９３年７月作者以个去甲氧基柔红霉素（ＩＤＡ）为主组成联合化疗方案治疗各种初治和复治的急性白血病共３６例，其中急性淋巴细胞白血病（ＡＬＬ）１５例，急性非淋巴细胞白血病（ＡＮＬＬ）２１例。ＡＬＬ组采用ＶＩＣＰ方案（其中ＩＤＡ１０～１５ｍｇ／ｄ，静脉注射，第１～３天和第１５～１７天）；ＡＮＬＬ组采用ＩＡ方案（其中ＩＤＡ１０～１５ｍｇ／ｄ，静脉注射，第１～３天）。结果表明ＩＤＡ安全、有效。初治ＡＬＬ的完全缓解（ＣＲ）率为７／１０（７０％），复治ＡＬＬ的ＣＲ率为１／５（２０％）；初治ＡＮＬＬ的ＣＲ率为６／１３例（４６％），复治ＡＮＬＬ的ＣＲ率为４／８例（５０％）。ＩＤＡ联合化疗的副作用与柔红霉素相仿，仍有一定的心脏毒性，在老年患者中应谨慎使用。hirty-six adult patients with newly diagnosed or re-fractory acute leukemias were treated with idarubicin(IDA) in combination with other chemotherapeuticagents. Fifteen patients with ALL received VICP regi-men (IDA, 10～15mg/d, iv on day 1～3 and 15～17).Twenty-one patients with ANLL received iA regimen(IDA 10～15mg/d ,iv , 3 days ). The complete remis-sion rates were 7/10 (70%) and 1/5 (20% ) in de novoALL and refractory ALL, and 6/13 (46%) and 4/8(50%) in newly diagnosed ANLL and refractory AN-LL , respectively. IDA in combination therapy had sim-ilar side effects to DAR. It should be given with care inelderly patients.

关 键 词：急性 白血病 4-去甲氧基 柔红霉素 药物疗法 

分 类 号：R733.710.5[医药卫生—肿瘤] R979.14[医药卫生—临床医学]